Reimagining Lymphatic Access
We introduce a breakthrough port-a-cath–style device specifically designed for congestive heart failure patients. This innovation is tailored to the lymphatic system, offering a novel approach to thoracic duct access while remaining grounded in empirical research and clinical safety.
Current approaches to managing fluid overload in CHF are primarily drug-based, relying on diuretics to remove excess fluid; however, 25–30% of patients develop resistance, limiting effectiveness. Previous strategies, including invasive surgeries and needle-based thoracic duct access, carried high risks of infection and were associated with significant mortality.
Clinical Interventions
The lymphatic system is a complex, low-pressure network of vessels that collects interstitial fluid and returns it to circulation. The thoracic duct, its largest vessel, runs from the cisterna chyli to the neck, draining most of the body and emptying into the left subclavian–jugular vein junction.
Intricate Anatomy
Lymphatic System
Function | Anatomy | Limitations
In congestive heart failure (CHF), elevated central venous pressure increases fluid filtration into tissues while impairing lymphatic drainage. Over time, inflammation and vessel dysfunction reduce lymphatic transport capacity, leading to fluid accumulation, edema, and worsening organ congestion.
Dysregulation
Intricate Anatomy
Dysregulation
Lack of Research
The lymphatic system is underexplored due to its complex anatomy and limited imaging options. While animal studies show that relieving lymphatic overload improves symptoms, poor visualization with conventional imaging has hindered human research and clinical translation.
Clinical Interventions
The lymphatic system is a complex, low-pressure network of vessels that collects interstitial fluid and returns it to circulation. The thoracic duct, its largest vessel, runs from the cisterna chyli to the neck, draining most of the body and emptying into the left subclavian–jugular vein junction.
Current approaches to managing fluid overload in CHF are primarily drug-based, relying on diuretics to remove excess fluid; however, 25–30% of patients develop resistance, limiting effectiveness. Previous strategies, including invasive surgeries and needle-based thoracic duct access, carried high risks of infection and were associated with significant mortality.